Cingulate (NASDAQ:CING) Announces Earnings Results

Cingulate (NASDAQ:CING) posted its earnings results on Tuesday. The company reported ($5.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($5.64) by $0.17, Zacks reports.

Cingulate Trading Up 129.3 %

Shares of NASDAQ:CING traded up $2.39 on Thursday, reaching $4.23. The company had a trading volume of 44,958,781 shares, compared to its average volume of 327,135. The firm’s 50 day simple moving average is $0.60 and its 200-day simple moving average is $0.93. Cingulate has a 52-week low of $1.80 and a 52-week high of $187.20.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.